Literature DB >> 23224432

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study.

Zhihong Ma1, Hongwei Li, Bin Wang, Qibin Shen, Enhai Cui, Lishan Min, Fuchu Qian, Jinliang Ping, Licheng Dai.   

Abstract

BACKGROUND AND OBJECTIVES: Midkine (MK) mRNA was highly expressed in various human cancer tissues and cells. The present study aimed to investigate whether MK mRNA level in peripheral blood mononuclear cells (PBMC) could serve as a diagnostic biomarker for patients having primary non-small cell lung cancer (NSCLC).
METHODS: MK mRNA level in PBMC from 87 patients with primary NSCLC, 35 patients with lung benign lesion (LEL), and 30 healthy volunteers was analyzed by real-time quantitative RT-PCR. The levels of serum carcinoembryonic antigen, carbohydrate antigen 125 (CA125), and neuron-specific enolase were detected by chemiluminescent microparticle enzyme immunoassay.
RESULTS: PBMC MK mRNA level was significantly higher in patients with primary NSCLC than that in other groups (P < 0.001), while there was no significant difference between LEL patients and healthy volunteers (P > 0.05). Higher MK mRNA level was correlated with clinical stages (P = 0.026), differentiation (P = 0.025), and lymph node metastasis (P = 0.022) of NSCLC. Using a cutoff of 0.0063, the sensitivity and specificity of MK mRNA levels to differentiate between patients with NSCLC and patients with LEL were 57.47 and 93.33 %,and it were 56.32 and 93.33 % for patients with NSCLC and healthy volunteers, respectively. Furthermore, multivariate analysis indicated that PBMC MK mRNA level above the cutoff value presented a chance of 11-fold higher for NSCLC occurrence.
CONCLUSIONS: MK mRNA level in PBMC may be a potential non-invasive molecular marker for the diagnosis of primary NSCLC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23224432     DOI: 10.1007/s00432-012-1357-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis.

Authors:  K Kadomatsu; M Tomomura; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.

Authors:  Hirokazu Hidaka; Hiroshi Yagasaki; Yoshiyuki Takahashi; Asahito Hama; Nobuhiro Nishio; Makito Tanaka; Nao Yoshida; Itzel Bustos Villalobos; Yue Wang; Yinyan Xu; Keizo Horibe; Sen Chen; Kenji Kadomatsu; Seiji Kojima
Journal:  Leuk Res       Date:  2007-01-30       Impact factor: 3.156

5.  Choice of endogenous control for gene expression in nonsmall cell lung cancer.

Authors:  D W Liu; S T Chen; H P Liu
Journal:  Eur Respir J       Date:  2005-12       Impact factor: 16.671

6.  Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC).

Authors:  Domenico Ferrigno; Gianfranco Buccheri; Cristina Giordano
Journal:  Lung Cancer       Date:  2003-09       Impact factor: 5.705

7.  Midkine mRNA is overexpressed in pancreatic cancer.

Authors:  Seiji Ohhashi; Kenoki Ohuchida; Kazuhiro Mizumoto; Takuya Egami; Jun Yu; Lin Cui; Hiroki Toma; Shunichi Takahata; Toshinaga Nabae; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

8.  Expression of midkine in the early stage of carcinogenesis in human colorectal cancer.

Authors:  C Ye; M Qi; Q W Fan; K Ito; S Akiyama; Y Kasai; M Matsuyama; T Muramatsu; K Kadomatsu
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

9.  Midkine as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  K Ota; H Fujimori; M Ueda; S Shiniriki; M Kudo; H Jono; Y Fukuyoshi; Y Yamamoto; H Sugiuchi; H Iwase; M Shinohara; Y Ando
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

10.  Increased midkine gene expression in human gastrointestinal cancers.

Authors:  K Aridome; J Tsutsui; S Takao; K Kadomatsu; M Ozawa; T Aikou; T Muramatsu
Journal:  Jpn J Cancer Res       Date:  1995-07
View more
  6 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

2.  Available active surveillance follow-up protocols for small renal mass: a systematic review.

Authors:  Giacomo Rebez; Nicola Pavan; M Carmen Mir
Journal:  World J Urol       Date:  2021-01-16       Impact factor: 4.226

3.  Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK).

Authors:  Jingyan Luo; Xiaoxiao Wang; Zhibo Xia; Lixuan Yang; Zhiming Ding; Shiyuan Chen; Bingquan Lai; Nu Zhang
Journal:  Mol Biol Cell       Date:  2014-11-26       Impact factor: 4.138

4.  Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia.

Authors:  Xiaodong Lyu; Yaping Xin; Ruihua Mi; Jing Ding; Xianwei Wang; Jieying Hu; Ruihua Fan; Xudong Wei; Yongping Song; Richard Y Zhao
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

5.  Prognostic value of Midkine expression in patients with solid tumors: a systematic review and meta-analysis.

Authors:  Luo Zhang; Xing Song; Yingjie Shao; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2018-01-04

6.  Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria.

Authors:  Hao Lin; Qingwen Zhou; Weichu Wu; Yulin Ma
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.